Argenx has filed a patent for antibodies and antigen binding fragments that have a strong affinity for the human CD70 protein and effectively inhibit the growth of tumor cells. GlobalData’s report on Argenx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Argenx SE - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Argenx, Personalized cancer vaccines was a key innovation area identified from patents. Argenx's grant share as of September 2023 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Antibodies for inhibiting tumor cell growth by binding cd70

Source: United States Patent and Trademark Office (USPTO). Credit: Argenx SE

A recently filed patent (Publication Number: US20230265201A1) describes a host cell that contains specific polynucleotides for producing antibodies that bind to human CD70. The host cell comprises a first polynucleotide encoding a heavy chain variable domain (VH) and a second polynucleotide encoding a light chain variable domain (VL). The VH includes specific amino acid sequences for the HCDR3, HCDR2, and HCDR1 regions, while the VL includes specific amino acid sequences for the LCDR3, LCDR2, and LCDR1 regions.

The patent claims also specify variations in the amino acid sequences of the VH and VL regions. For example, the VH sequence can be at least a certain percentage identical to a specific reference sequence (SEQ ID NO: 223), and the VL sequence can be at least a certain percentage identical to another reference sequence (SEQ ID NO: 241).

The host cell can be a Chinese hamster ovary cell, which is commonly used in biotechnology for producing therapeutic proteins. The polynucleotides encoding the VH and VL regions can be present within a single vector or separate vectors.

The patent also describes methods of producing antibodies that specifically bind to human CD70 using the host cell. The methods involve culturing the host cell so that the polynucleotides are expressed and the antibody is produced. In some embodiments, the produced antibody can be non-fucosylated, which may have certain advantages in terms of therapeutic efficacy.

Overall, this patent provides a detailed description of a host cell and methods for producing antibodies that target human CD70. The specific amino acid sequences and variations described in the patent may be valuable for the development of therapeutic antibodies for various applications, such as cancer treatment.

To know more about GlobalData’s detailed insights on Argenx, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies